Population Health Research Institute
Study List

OASIS-3/CREATE-ECLA (Completed)
The Clinical Trial of REviparin and Metabolic Modulation in Acute Myocardial Infaction Treatment Evaluation

< back

The trial evaluated effects of high-dose glucose, insulin, and potassium (GIK) on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. GIK infusion in patients with STEMI had no significant impact on mortality and other major cardiac events.

Study Design: Randomized controlled trial with partial 2x2 factrial design.

Intervention: High-dose glucose, insulin, and potassium (GIK) vs. placebo.

Length of Study: 6 years

# of Patients: 20,201 

Patient Populations: ST-segment elevation acute myocardial infarction.


Presentations

CREATE - Reviparin & GIK - Final Results


Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, Zhu J, Liu L; CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293(4): 427-35.

Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005 Jan 26;293(4):437-46.

 

 

 

 

 

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca